Grifols (NASDAQ:GRFS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
A number of other equities analysts also recently issued reports on the company. HSBC raised Grifols from a “reduce” rating to a “hold” rating in a research report on Wednesday, March 14th. Morgan Stanley reduced their price target on Grifols from $23.00 to $22.00 and set an “underweight” rating on the stock in a research report on Thursday, March 1st. BidaskClub downgraded Grifols from a “hold” rating to a “sell” rating in a research report on Wednesday, February 28th. Finally, ValuEngine raised Grifols from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $22.50.
Shares of GRFS stock opened at $20.30 on Wednesday. The firm has a market cap of $14,175.41, a PE ratio of 18.45, a price-to-earnings-growth ratio of 1.31 and a beta of 1.19. The company has a debt-to-equity ratio of 1.62, a quick ratio of 1.35 and a current ratio of 3.01. Grifols has a 12-month low of $19.92 and a 12-month high of $25.18.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pitcairn Co. acquired a new position in shares of Grifols in the 4th quarter valued at $228,000. Two Sigma Advisers LP increased its position in shares of Grifols by 252.1% in the 4th quarter. Two Sigma Advisers LP now owns 214,100 shares of the biotechnology company’s stock valued at $4,907,000 after acquiring an additional 153,300 shares during the period. Engadine Partners LLP acquired a new position in shares of Grifols in the 4th quarter valued at $39,350,000. First Trust Advisors LP increased its position in shares of Grifols by 3.7% in the 4th quarter. First Trust Advisors LP now owns 1,878,401 shares of the biotechnology company’s stock valued at $43,053,000 after acquiring an additional 67,501 shares during the period. Finally, Aperio Group LLC increased its position in shares of Grifols by 6.5% in the 4th quarter. Aperio Group LLC now owns 316,471 shares of the biotechnology company’s stock valued at $7,254,000 after acquiring an additional 19,204 shares during the period. 22.27% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/25/grifols-grfs-downgraded-by-zacks-investment-research-to-hold-2.html.
Grifols Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Get a free copy of the Zacks research report on Grifols (GRFS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.